Eritoran
Modify Date: 2024-01-09 20:04:40
Eritoran structure
|
Common Name | Eritoran | ||
|---|---|---|---|---|
| CAS Number | 185955-34-4 | Molecular Weight | 1401.58000 | |
| Density | 1.14 | Boiling Point | N/A | |
| Molecular Formula | C66H122N2Na4O19P2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EritoranEritoran is a Toll-like receptor 4 (TLR4) antagonist. Eritoran protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran inhibits pathogenesis of filovirus infection[1]. |
| Name | [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate |
|---|---|
| Synonym | More Synonyms |
| Description | Eritoran is a Toll-like receptor 4 (TLR4) antagonist. Eritoran protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran inhibits pathogenesis of filovirus infection[1]. |
|---|---|
| Related Catalog | |
| Target |
TLR4 |
| In Vivo | Eritoran (233 μg/小鼠；腹腔注射；10 天) 保护小鼠免受 EBOV 致死性感染，实验结束时保有 70% 的生存率[1]。 Animal Model: C57BL/6J mice challenged with lethal EBOV[1] Dosage: 233 μg/mouse Administration: Intraperitoneal injection; 10 days Result: Reduced granulocytosis and results in a higher percentage of activated CD11b+ Ly6G/Ly6C+ neutrophils. Dramatically reduced the levels of IFN-γ-secreting CD8+ and CD4+ T cells and IL-17A-secreting CD4+ T cells. |
| References |
| Density | 1.14 |
|---|---|
| Molecular Formula | C66H122N2Na4O19P2 |
| Molecular Weight | 1401.58000 |
| Exact Mass | 1400.77000 |
| PSA | 324.57000 |
| LogP | 16.14580 |
| Eritoran [INN] |